205 related articles for article (PubMed ID: 20479289)
1. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.
Ndonwi M; Tuley EA; Broze GJ
Blood; 2010 Aug; 116(8):1344-51. PubMed ID: 20479289
[TBL] [Abstract][Full Text] [Related]
2. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
Piro O; Broze GJ
Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
[TBL] [Abstract][Full Text] [Related]
4. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S.
Ahnström J; Andersson HM; Hockey V; Meng Y; McKinnon TA; Hamuro T; Crawley JT; Lane DA
Blood; 2012 Dec; 120(25):5059-62. PubMed ID: 23074276
[TBL] [Abstract][Full Text] [Related]
5. TFPI-dependent activities of protein S.
Peraramelli S; Rosing J; Hackeng TM
Thromb Res; 2012 May; 129 Suppl 2():S23-6. PubMed ID: 22425215
[TBL] [Abstract][Full Text] [Related]
6. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
[TBL] [Abstract][Full Text] [Related]
7. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
8. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain.
Reglińska-Matveyev N; Andersson HM; Rezende SM; Dahlbäck B; Crawley JT; Lane DA; Ahnström J
Blood; 2014 Jun; 123(25):3979-87. PubMed ID: 24740810
[TBL] [Abstract][Full Text] [Related]
9. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
[TBL] [Abstract][Full Text] [Related]
10. Zn²(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor.
Fernandes N; Mosnier LO; Tonnu L; Heeb MJ
J Thromb Haemost; 2010 Sep; 8(9):1976-85. PubMed ID: 20492471
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.
Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ
Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726
[TBL] [Abstract][Full Text] [Related]
12. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
13. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):169-76. PubMed ID: 24233490
[TBL] [Abstract][Full Text] [Related]
14. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
Lockett JM; Mast AE
Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
[TBL] [Abstract][Full Text] [Related]
15. Protein S is a cofactor for tissue factor pathway inhibitor.
Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM
Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502
[TBL] [Abstract][Full Text] [Related]
16. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition.
Salemink I; Franssen J; Willems GM; Hemker HC; Lindhout T
J Biol Chem; 1999 Oct; 274(40):28225-32. PubMed ID: 10497177
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
19. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
